General reagents and methods:
All the reagents and solvents were obtained from commercial sources and used without further purification. All the reactions involving Cy5 and Cy7 were carried out under dark or shielded from light. HPLC characterizations and purifications were performed on Agilent 1100 or 1200 with reverse-phase C 18 column (Phenomenex) using acetonitrile and water solvent system with 0.05% TFA as additive. Low resolution electrospray ionization (ESI) mass spectrometry was performed using Agilent HPLC connected to an Agilent LCMS trap XCT. UV absorbance was recorded on Cary 3E (Varian) or UV-2700 (Shimadzu) . Fluorescence was recorded in quartz cuvets using a spectrofluorometer (FluoroLog®, Horiba Scientific).
All the RACPPs were pegylated with mPeg12 to prevent aggregation and to improve solubility (1) was prepared using conventional solid phase Fmoc peptide synthesis (Prelude, Peptide Technologies, Inc), where lower case letters refer to D-amino acids, "o" denotes 5-amino-3oxopentanoyl (a short hydrophilic spacer), C(Me) denotes S-methylcysteine and the final CONH 2 indicates C-terminal amide. The peptide was isolated from the solid support by treating it with mixtures of 92% trifluoroacetic acid (TFA), 2% thioanisole, 2% water and 4% triisopropylsilane (TIPS) for 5 h under N 2 atmosphere and filtered. This filtrate was concentrated and then precipitated by addition of ice cold 50% hexanes in methyl tert-butyl ether mixture.
Centrifugation was performed to isolate the pellet that was dried under high vacuum. The peptide was dissolved in dimethyl sulfoxide (DMSO) and purified by high performance liquid chromatography (HPLC) using 5-55% acetonitrile in water and 0.05% TFA. The purified product
(1) was dried by lyophilization (mass obtained 3695.7 Da, mass calculated 3696.1 Da).
To the purified compound 1 (20 mg) was added anhydrous DMSO (1 mL) Cy5 maleimide (Cy5-Maleimide, ~ 3 mg, synthesized from the NHS ester 1 by reaction with 2-aminoethylmaleimide and N-methylmorpholine (NMM) in DMSO, followed by precipitation with ethyl acetate), NMM (1L) under N 2 atmosphere and reacted for 3 h. To this reaction mixture (contains compound 2, mass obtained 4474.8.0 Da, mass calculated 4275.0 Da, purification at this step is not necessary) triethyl phosphine (TEP, 25 L) was added and kept at room temperature for another 6 h. 3 was precipitated by addition of ice cold 50 % hexanes in methyl tert-butyl ether mixture. The precipitate was collected by centrifugation, dried under high vacuum and purified by HPLC using 15-45% acetonitrile gradient in water and 0.05% to give NH 2 -e9-c(SH)-oDPRSFL-r9-c(Cy5)-CONH 2 (3, mass obtained 4386.6 Da, mass calculated 4386.8 Da ). To a dry reaction vessel, was added compound 3 (6 mg), DMSO (0.4 mL, anhydrous), m-dPEG12-Mal (2 mg, Quanta Biodesign, product number 10289) and NMM (0.5 L) under N 2 atmosphere, reacted at room temperature for 12 h and purified by HPLC using 7-50% acetonitrile gradient in water and 0.05% TFA to give 4 mass obtained 5097.6 Da, mass calculated 5097.7 Da). To a dry reaction vessel was added compound 4 (4 mg), Cy7 NHS ester (~0.60 mg, from GE life sciences), DMSO (0.4 mL), and NMM (1L) and reacted at room temperature for 24 h. The product was purified by HPLC using 15-45% acetonitrile gradient in water and 0.05% TFA to give RACPP DPRSFL (5, mass obtained 5762.0 Da, mass calculated = 5762.5 Da, Figure S4a ,).
All the other RACPPs (10, 15, 20 and 25) were synthesized according to general scheme 1 and followed a similar synthetic protocol as that of RACPP DPRSFL (5). Analytical HPLC combined with mass spectrometry was used to confirm the identity of the compounds (Tables S1 and S2).
Purity of the final compounds was assessed by analytical HPLC ( Figure S5 ) using 5-55% acetonitrile in water gradient over 25 mins at 1 ml/min flow rate. (20) by 100 nM MMP-9 or thrombin. Digested peptides were separated on 4% agarose gels in 50 mM pentaethylenehexamine-acetate at pH 5.6. Gels were imaged for a) Cy5 fluorescence, b) Cy7 fluorescence upon exciting Cy5, brightened 6-fold, and c) Cy7 fluorescence. Panel d) is an overlay of a) in red, b) in green, and c) in blue. Panel e) is a pseudocolor Cy5/Cy7 emission ratio image of panels a) and b), generated as in Fig. 2 and 3 . The two RACPPs were run on separate gels with the electrophoretic polarity shown between them. The thin white separation in the RACPP PLGC(Me)AG gel marks where irrelevant lanes and specular reflections were excised for clarity. 
Probe analysis using SDS polyacrylamide gel electrophoresis
Prior to gel electrophoresis 1 µM of each RACPP were cleaved in 150 mM NaCl, 20 mM Tris pH 7.5, 2 mM CaCl 2 , 1% BSA, 50 nM enzyme at 37°C. Purified thrombin, plasmin, factor Xa, and MMP-9 (activated) were purchased from EMD Chemicals. Samples were mixed with tricine SDS gel loading buffer and heated to 95°C for 5 min before loading in 10-20% tricine gels for electrophoresis. Images were taken on a Maestro multispectral imager (CRI Inc.) with 620 nm excitation and collection for Cy5 (660 to 720 nm) and Cy7 (760 to 830 nm) emission, respectively. Ratiometric images were synthesized by dividing the Cy5 emission by the Cy7 emission. Pseudocolors from blue (ratio minimum) to red (ratio maximum) were assigned using custom designed software.
Probe analysis using PEHA-Acetate agarose gel electrophoresis RACP PLGC(Me)AG and RACPP PPRSFL were cleaved in 150 mM NaCl, 20 mM Tris pH 7.5, 2 mM CaCl 2 or 2 X PBS buffer with 100 nM MMP-9 or thrombin at 37°C respectively. Samples were mixed with PEHA (80 mM pentaethylenehexamine neutralized with acetic acid to make pH 5.6) buffer containing 15% glycerol, loaded on 4% agarose gel in 50 mM PEHA-Acetate pH 5.6, electrophoretically separated, and imaged as above. 
